Cetera Advisor Networks’s Neurocrine Biosciences NBIX Stock Holding History

Cetera Advisor Networks’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$663K	Sell	4,806 -941	-16%	-$129K	﹤0.01%	1743
2023 Q4	$757K	Buy	5,747 +9	+0.2%	+$1.04K	﹤0.01%	1567
2023 Q3	$646K	Buy	5,738 +1,481	+35%	+$156K	﹤0.01%	1590
2023 Q2	$401K	Buy	4,257 +1,665	+64%	+$163K	﹤0.01%	1877
2023 Q1	$262K	Buy	2,592 +441	+21%	+$45.9K	﹤0.01%	2135
2022 Q4	$257K	Buy	+2,151	New	+$252K	﹤0.01%	2097
2020 Q3	–	Sell	-103	Closed	-$13K	–	2366
2020 Q2	$13K	Buy	+103	New	+$11.4K	﹤0.01%	2607

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Cetera Advisor Networks's NBIX Position: Q1 2024 in Review

Cetera Advisor Networks reduced its Neurocrine Biosciences (NBIX) stake by 16% in Q1 2024, selling an estimated $129K and leaving 4,806 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Cetera Advisor Networks first reported a position in NBIX in Q2 2020 and has held it in 7 quarters since. The position peaked at $757K in Q4 2023. 590 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

Cetera Advisor Networks held 4,806 shares of Neurocrine Biosciences worth $663K as of Q1 2024.
Cetera Advisor Networks sold 941 Neurocrine Biosciences shares in Q1 2024, an estimated $129K.
Neurocrine Biosciences made up ﹤0.01% of Cetera Advisor Networks's portfolio in Q1 2024, its #1743 holding.
Cetera Advisor Networks first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 7 quarters since.
Cetera Advisor Networks's Neurocrine Biosciences position peaked at $757K in Q4 2023.
590 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Cetera Advisor Networks's 13F filing for Q1 2024, filed 15 May 2024.